Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Since the COVID-19 pandemic began a little more than a year ago, scientists have sequenced the virus' genome, developed vaccines to prevent its spread,.
Credit: Tatjana Hirschmugl
A new study exploits the characteristic epigenetic signatures of childhood tumors to detect, classify and monitor the disease. The scientists analyzed short fragments of tumor DNA that are circulating in the blood. These liquid biopsy analyses exploit the unique epigenetic landscape of bone tumors and do not depend on any genetic alterations, which are rare in childhood cancers. This approach promises to improve personalized diagnostics and, possibly, future therapies of childhood tumors such as Ewing sarcoma. The study has been published in
Nature Communications.
A study led by scientists from St. Anna Children s Cancer Research Institute (St. Anna CCRI) in collaboration with CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences provides an innovative method for liquid biopsy analysis of childhood tumors. This method exploits the fragmentation patterns of the small DNA fragments that tumors leak into the blood stream, whi
Monitoring the potency of cell therapies using bioelectronic assays
2
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Personalised medicine is now within reach for thousands of cancer patients thanks to immunotherapies such as CAR T cells. This cell therapy involves training a patient’s immune system through genetic engineering to recognise tumour cells as foreign bodies and attack them directly, without attacking healthy tissue. In 2017, the US Food and Drug Administration (FDA) approved Kymriah, the first CAR T-cell therapy, for the treatment of B-cell acute lymphoblastic leukaemia. Now, patients across the US can access the treatment at any one of over 130 treatment centers.